AngioSoma, Inc. (OTC: SOAN) Announces Completion of Products for Market
HOUSTON — February 5, 2018
We are pleased to announce we are launching a line of supplements under our Somaceuticals^TM common identity to be marketed on our upcoming website to be named soma-ceuticals.com. Our supplements cover three industry segments:nutraceuticals, cosmeceuticals, and pharmaceuticals.
Nutraceuticals lead off with StemStrength^TM, ^ an all-natural stimulant for accelerated muscle and tissue development and RockOn^TM, a potent libido complex tonic for male and female usage, containing popular ingredients for sexual health.
Cosmeceuticals include three products:
Rapid Wrinkle Reducer: a skin-smoothing serum gentle enough for everyday use. Instant results from plant extracts help reduce the appearance of fine lines and wrinkles and help to combat the appearance of aging skin.
Powerful Peptide Eye Serum: helps to reduce the appearance of eye bags, dark circles, and puffy eyes by relieving the accumulation of fluids and increasing the firmness around your eyes.
Collagen Anti-Aging Crème: nourishes and protects skin while encouraging skin cell renewal. It supports elastin and collagen production, which promotes skin moisture, elasticity, and thickness. It also has a healing effect on troubled or damaged skin areas.
Our lead pharmaceutical drug candidate is Liprostin^TM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD).
Liprostin^TM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations (‘CRO’) for completion of our U.S. Food and Drug Administration (‘FDA’) protocol for Phase
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD‘). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA‘) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.